INT117660

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 2003
Last Reported 2011
Negated 7
Speculated 0
Reported most in Body
Documents 50
Total Number 55
Disease Relevance 39.62
Pain Relevance 3.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Prom1) plasma membrane (Prom1) cilium (Prom1)
Anatomy Link Frequency
stem 6
stem cells 5
liver 2
precursor cells 2
macrophages 1
Prom1 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 114 99.66 Very High Very High Very High
imagery 1023 97.64 Very High Very High Very High
neurotrophin 3 48 87.72 High High
anesthesia 47 83.20 Quite High
Pain 2 80.96 Quite High
Inflammation 167 80.08 Quite High
Spinal cord 46 61.00 Quite High
Morphine 3 50.00 Quite Low
chemokine 4 38.84 Quite Low
alcohol 3 25.76 Quite Low
Disease Link Frequency Relevance Heat
Glioma 349 100.00 Very High Very High Very High
Injury 487 99.98 Very High Very High Very High
Cancer 3176 99.86 Very High Very High Very High
Central Nervous System Cancer 3 99.76 Very High Very High Very High
Glioblastoma 444 99.72 Very High Very High Very High
Colon Cancer 97 99.66 Very High Very High Very High
Brain Tumor 363 99.60 Very High Very High Very High
Viral Infection 83 99.40 Very High Very High Very High
Skin Cancer 60 98.88 Very High Very High Very High
Adenocarcinoma 6 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The CD133 expression in the original human glioblastoma and its transplants
Gene_expression (expression) of CD133 associated with glioblastoma
1) Confidence 0.73 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2907866 Disease Relevance 1.10 Pain Relevance 0.06
Another problem encountered during our studies is the decrease of CD133 expression in HCT116 tumor xenografts.
Gene_expression (expression) of CD133 associated with cancer
2) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.71 Pain Relevance 0.12
The AC133 and AC141 epitopes are expressed on normal tissue stem and progenitor cells such as hematopoietic stem and endothelial progenitor cells [10], [37].
Gene_expression (expressed) of AC133 in stem
3) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.62 Pain Relevance 0.03
In gliomas, the frequency of cells expressing CD133 (AC133) increases with tumor grade [14].
Gene_expression (expressing) of AC133 associated with cancer and glioma
4) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 1.32 Pain Relevance 0.06
A decrease of the CD133 expression levels in vivo might provide an explanation for the apparently smaller difference in CD133 expression in vivo compared to in vitro.
Gene_expression (expression) of CD133
5) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.24 Pain Relevance 0
Cells with CD133 expression lower than that of HCT116 wild-type cells may be hard to identify unequivocally with this imaging method unless a proper negative control is available.
Gene_expression (expression) of CD133 associated with imagery
6) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.83 Pain Relevance 0.12
A decrease of the CD133 expression levels in vivo might provide an explanation for the apparently smaller difference in CD133 expression in vivo compared to in vitro.
Gene_expression (expression) of CD133
7) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.29 Pain Relevance 0
The relative surface CD133 expression levels of the positive cell lines were determined measuring their AC133.1 antibody saturation concentration via flow cytometry.
Gene_expression (expression) of CD133
8) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.36 Pain Relevance 0.06
In gliomas, the frequency of cells expressing CD133 (AC133) increases with tumor grade [14].
Gene_expression (expressing) of CD133 associated with cancer and glioma
9) Confidence 0.71 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 1.31 Pain Relevance 0.06
Indeed, when compared to in vitro cultured cells, HCT116 wild-type cells isolated from xenografts exhibited lower CD133 expression (Figure 4C).
Gene_expression (expression) of CD133
10) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.24 Pain Relevance 0
The saturation point for AC133.1 on CD133-overexpressing U251 cells was found to be 2.8×10?
Gene_expression (point) of CD133-overexpressing
11) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.41 Pain Relevance 0.06
In order to test whether the AC133.1 antibody could detect CD133 expression in vivo, CD133-overexpressing and wild-type U251 cells were subcutaneously (s.c.) implanted into nude mice (for a tumor growth curve, see Figure S1).
Gene_expression (expression) of CD133 associated with cancer
12) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.46 Pain Relevance 0.08
Another CSC marker found in a multitude of tumor entities is CD133/prominin.
Gene_expression (/) of CD133 associated with cancer
13) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.48 Pain Relevance 0
10 M, establishing the CD133 expression level difference between HCT116 wild-type cells and the CD133-overexpressing U251 cell line at ca. sixtyfold (Figure 1D).
Gene_expression (expression) of CD133
14) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.42 Pain Relevance 0.07
Meanwhile, CD133/prominin (AC133) has been identified as a CSC marker for brain tumors including glioblastoma, ependymoma and medulloblastoma, as well as for a variety of non-nervous system tumors such as pancreatic, colon, bronchial, prostate, ovarian and liver cancer, melanoma, and leukemia [12], [13].
Gene_expression (/) of CD133 in liver associated with liver cancer, leukemia, nervous system cancer, glioblastoma, medulloblastoma, ependymoma, skin cancer and brain tumor
15) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 1.09 Pain Relevance 0
In addition, they show that antibody-based targeting of CD133 (AC133) is efficient.
Gene_expression (targeting) of AC133
16) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.25 Pain Relevance 0.14
In addition, they show that antibody-based targeting of CD133 (AC133) is efficient.
Gene_expression (targeting) of CD133
17) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.25 Pain Relevance 0.14
Meanwhile, CD133/prominin (AC133) has been identified as a CSC marker for brain tumors including glioblastoma, ependymoma and medulloblastoma, as well as for a variety of non-nervous system tumors such as pancreatic, colon, bronchial, prostate, ovarian and liver cancer, melanoma, and leukemia [12], [13].
Gene_expression (/) of AC133 in liver associated with liver cancer, leukemia, nervous system cancer, glioblastoma, medulloblastoma, ependymoma, skin cancer and brain tumor
18) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 1.10 Pain Relevance 0
We also found that a small population of CD133-negative cells in the tumors bound injected AC133.1-Alexa488.
Neg (negative) Gene_expression (injected) of AC133 associated with cancer
19) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.24 Pain Relevance 0
Any potential diagnostic and therapeutic use of CD133-specific antibodies in humans would require further investigations on the expression pattern and level of CD133 epitopes in normal tissues and the degree of specificity/cross-reactivities of available CD133-specific mAbs.
Gene_expression (expression) of CD133
20) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004948 Disease Relevance 0.69 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox